Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression - 09/05/15
Aleksandar Sekulic, Mayo Clinic, Scottsdale, AZ, United States; John D. Hainsworth, Sarah Cannon Research Institute, Nashville, TN, United States; Karl D. Lewis, University of Colorado Cancer Center, Aurora, CO, United States; Anthony E. Oro, Stanford University School of Medicine, Stanford, CA, United States; Anja Gesierich, Universitätsklinikum Würzburg, Würzburg, Germany; Laurent Mortier, Center Hospitalier Regional Universitaire de Lille, Lille, France; Luc Dirix, Sint-Augustinus Hospital, Antwerp, Belgium; Stephen Bernard, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States; Brigitte Dreno, CHU Hôtel-Dieu, Nantes, France; Dedee F. Murrell, Premier Specialists, University of New South Wales, Sydney, Australia; Sarah Williams, Roche Products Ltd., Welwyn Garden City, United Kingdom; Jeannie Hou, Genentech, Inc, South San Francisco, CA, United States; David Fisher, Harvard University, Boston, MA, United States
Le texte complet de cet article est disponible en PDF.| Funded by Roche-Genentech. |
Vol 72 - N° 5S1
P. AB195 - mai 2015 Retour au numéro
Article précédent
- Video-based education for basal cell carcinoma treatment: A pilot study
- A complex course: Referral paths to pediatric dermatology
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?